Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- FDA Approves New Indication for ZETIA® - Merck/Schering-Plough's Cholesterol Lowering Drug - For Administration in Combination with Fenofibrate, along With Diet
- WHITEHOUSE STATION & KENILWORTH, N.J. -- Expanded Indication for ZETIA Offers a New Treatment Alternative for Patients with Mixed Hyperlipidemia
- Research articles 2006-06-09
- Schering-Plough, Merck score big. (Life Sciences).(receives FDA approval for cholesterol drug, Zetia)
- THE $19 BILLION cholesterol market has been jolted by Food and Drug Administration FDA approval of Zetia ezetimibe, the first new class of drug behind a 15-year reign by statins. The development is good news for Schering-Plough Corp. SHP and THE $19 BILLION...
- Research articles 2002-11-04
- Cholesterol boost for AstraZeneca.
- AstraZeneca's drug Crestor has produced the biggest reduction in bad cholesterol ever seen in a trial of 'statin' drugs, when used in combination with Merck's cholesterol absorption inhibitor Zetia. Data presented at a conference this week showed tha AstraZeneca's drug Crestor has produced the biggest reduction...
- Research articles 2006-06-23
- Enhancing employee health
- What's for lunch today? Pizza and potato chips? Fish and salad? We love choices at mealtime, but many of us make poor ones by eating too many fatty foods. That's why millions of Americans have high cholesterol, a major risk factor for heart disease and st What's for lunch today?...
- Research articles 2006-06-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
Additional Resources
- Leerink Outlines Gloom Potential for Merck/Schering's $2B Zetia Franchise
- Analysts at Leerink Swann have unearthed more somewhat speculative evidence that the result of Merck and Schering-Plough's "Arbiter 6" comparison of their Zetia cholesterol drug versus Abbott Labs' Niaspan went badly for Zetia. by Jim Edwards
- Blog posts 2009-08-17
- African Americans Should Not Stop Taking Vytorin or Zetia Without Consulting Their Healthcare Providers
- To: MEDICAL EDITORS Contact: Keith Ferdinand, MD, +1-404-201-6632 ATLANTA, Jan. 24 /PRNewswire/ -- The recent release of the ENHANCE study of Vytorin and Zetia has drawn considerable media attention, but stopping cholesterol medications based on this study alone is not appropriate. The next step for any concerned patient with...
- Research articles 2008-01-24
- UPDATED: Why Zetia Researchers' Silence on Ending of Niaspan Trial Is Unfair to Merck
- Dr. Allen Taylor, an ARBITER-6 HALT trial investigator, should probably avoid talking to Merck investors for the next few weeks lest he get punched in the nose. It was Allen and his colleagues' unexplained announcement that they had stopped an Abbott Labs-funded comparison of Merck's Zetia with Abbott's Niaspan that...
- Blog posts 2009-07-10
- Leerink Bets Abbott's Niaspan Beat Merck/Schering's Zetia in Mystery Trial
- Wall Street analysts at Leerink Swann are betting that Abbott Labs' Niaspan did indeed beat Merck/Schering-Plough's Zetia in the ARBITER 6 imaging study. That was the study that was suddenly and mysteriously halted without explanation, causing a rash of speculation. by Jim Edwards
- Blog posts 2009-07-17
- Vytorin and Zetia continue to be prescribed despite hints of harms and no proof of benefit
- There is no proof that Zetia can do anything beyond lowering cholesterol--no evidence that it can reduce heart attacks or cardiovascular disease, which, of course, is the ultimate goal. Once again, this blockbuster drug sold alone or as a combination medicine has produced negative clinical trial results. This time it...
- Research articles 2008-10-01
- Amateur Hour at Merck: FDA Refuses to Look at Zetia-Lipitor Combo Pill
- Merck was sent back to the drawing board on its new Zetia-Lipitor combo drug when the FDA refused to accept its application. That's an unheard of gaffe for a Big Pharma firm. Merck slipped the news into its 10-Q filing with the SEC. by Jim Edwards
- Blog posts 2009-11-04
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
- Is Merck Hanging Schering Out to Dry on Vytorin?
- Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-07-07
- Schering-Plough Now in the Feds' Crosshairs
- Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
- Discussion threads 2008-07-10
- Is Merck Hanging Schering Out to Dry on Vytorin?
- A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
- Blog posts 2008-04-23
- Merck & Co. Inc. Q3 2008 Earnings Conference Call Transcript
- Question-and-Answer Session[Operator Instructions] Your first question comes from the line of Tim Anderson of Bernstein. Tim Anderson - Bernstein Hi. Thank you. A couple of questions. Dick, I am hoping you can talk about the notion of having a so called established products group, like one of your competitors...
- Earnings calls 2008-10-22
- Schering-Plough Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Tim Anderson. Tim Anderson - Sanford Bernstein Thank you. Couple of questions. On golimunab, if I look at average European approval timelines it suggests you would get a decision in the first half of '09. Is that...
- Earnings calls 2009-02-03
- Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew
- About 1,000 sales reps are being let go from Schering-Plough this week. That's on top of 60 animal health reps also being fired. Roughly 5,500 employees in general are being axed in Schering-Plough's cost-cutting drive. If you're one of those people, comfort yourself with the fact that...
- Blog posts 2008-09-19
- Schering-Plough Now in the Feds' Crosshairs
- The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries.  Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
- Blog posts 2008-05-07
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
